Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342625 | 0.81 | ICMT (0.41) | ICMTMAP2K2MAP2K1ALDH1A1 | |
| SCHEMBL28131995 | 0.76 | ICMT (0.47) | KDM4EICMTMAP2K2MAP2K1NR4A2 | |
| SCHEMBL3341266 | 0.73 | KDM4E (0.40) | KDM4ENR4A2POLBKMT2AMITF | |
| SCHEMBL18911886 | 0.72 | MAP2K1 (0.42) | KDM4EMAP2K2MAP2K1KDM1AALDH1A1 | |
| SCHEMBL31693354 | 0.71 | KDM4E (0.45) | KDM4ENR4A2POLBKMT2AMITF | |
| SCHEMBL22450681 | 0.70 | KDM4E (0.54) | KDM4EICMTMAP2K2MAP2K1NR4A2 | |
| SCHEMBL3339082 | 0.70 | KDM4E (0.43) | KDM4ENR4A2POLBKMT2AMITF | |
| SCHEMBL13114466 | 0.70 | KDM4E (0.64) | KDM4EMAP2K2MAP2K1NR4A2POLB | |
| SCHEMBL2174829 | 0.68 | NR4A2 (0.65) | KDM4ENR4A2POLBKMT2AMITF | |
| SCHEMBL3341415 | 0.67 | GAA (0.33) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | KDM4E 2644/4885ICMT 4272/4885MAP2K2 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.